Welcome to our dedicated page for Quantum-Si news (Ticker: QSI), a resource for investors and traders seeking the latest updates and insights on Quantum-Si stock.
Quantum-Si Incorporated develops proteomics technology for single-molecule protein sequencing and protein analysis. Its updates center on benchtop platform development, real-time kinetic-based detection, and product work around Proteus instruments, the KinetIQ Array and Platinum Pro customer use.
Recurring company news includes quarterly financial results and non-GAAP operating measures, Proteus prototype and integrated-instrument sequencing milestones, amino-acid detection coverage, customer sample testing, scientific posters and manuscripts using Quantum-Si technology, investor conference participation, and equity-inducement grants under Nasdaq rules.
Quantum-Si (Nasdaq: QSI) announced that its Board's Compensation Committee has granted 340,460 restricted stock units (RSUs) to a new employee under the 2023 Inducement Plan. The RSUs will vest 25% on December 20, 2025, with the remaining vesting in 12 equal quarterly installments thereafter, subject to continued employment. The grant complies with Nasdaq Listing Rule 5635(c)(4) and serves as an inducement for new employees who were not previously with the company.
Quantum-Si (Nasdaq: QSI) has been awarded Frost & Sullivan's 2024 Technology Innovation Leadership Award in North America for its groundbreaking Platinum® instrument, the first benchtop sequencer offering single-molecule protein sequencing at the amino acid level. The technology enables deep insights into protein structure and function through a compact, accessible, and cost-effective instrument. The Platinum device integrates proprietary image sensors for single-molecule detection and precision sequencing, making protein research more accessible to labs of all sizes. The company's innovation is backed by an extensive intellectual property portfolio of over 1,000 issued and pending patents.
Quantum-Si (QSI) reported Q3 2024 financial results with revenue of $787,000 and gross margin of 47%. The company experienced sales pipeline acceleration but noted lengthening sales cycles, making it unlikely to achieve the full-year revenue guidance of $3.7-4.2 million. Operating expenses were $28.5 million, with a net loss of $25.3 million. Cash position stands at $196.3 million, providing runway into H2 2026. New library preparation and barcoding kits remain on track for Q4 launch. The company appointed Todd Bennett as CCO, highlighting improved commercial execution despite market challenges.
Quantum-Si (QSI) announced a new preprint publication demonstrating their Platinum single-molecule benchtop sequencer's capabilities in distinguishing proteoform-informative peptides within human tropomyosin genes. The study, led by Dr. Gloria Sheynkman at the University of Virginia School of Medicine, showcases Platinum's ability to achieve single amino acid resolution, differentiating TPM1 and TPM2 paralogous peptides and resolving phosphotyrosine modifications and TPM2 splice variants. The technology demonstrates advantages over traditional mass spectrometry techniques, particularly in detecting sequences with challenging molecular weights.
Quantum-Si (Nasdaq: QSI), The Protein Sequencing Company™, has announced its participation in two upcoming investment conferences. CEO Jeff Hawkins will engage in fireside chat discussions at the UBS Global Healthcare Conference on November 13th at 8:45 AM PT and the Canaccord Medtech, Diagnostics & Services Forum in New York City on November 21st at 8:00 AM ET. Both events will be available via live and archived webcasts in the 'Investors' section of Quantum-Si's website under Events & Presentations.
Quantum-Si (Nasdaq: QSI), The Protein Sequencing Company™, has announced an upcoming Investor & Analyst event scheduled for November 20th, 2024, from 10AM to 12PM EST at the Westin NY Times Square. The event will feature presentations from the company's management team, focusing on their technology roadmap, protein sequencing applications, and expanding commercial opportunities. The event includes a live Q&A session.
While in-person attendance is restricted to invited research analysts and institutional investors, others can participate virtually through the company's investor relations website. The webcast recording will remain accessible for at least 90 days after the event.
Quantum-Si (Nasdaq: QSI) announced its participation in the 2024 American Society of Human Genetics Annual Meeting, where it will present on Next-Generation Protein Sequencing (NGPS) technology. The presentation, titled 'From Prediction to Protein: Validating Transcriptomics Data with Quantum-Si's Next-Generation Protein Sequencing Technology,' will feature Dr. Meredith Carpenter and Dr. Colette Felton from UC Santa Cruz.
The presentation will demonstrate how NGPS technology validates transcriptomics predictions by confirming protein presence, abundance, and modifications. Dr. Felton will discuss using long-read RNA sequencing to detect variants in cancer genes and applying NGPS for protein-level validation. Quantum-Si will be available at booth #465 during ASHG 2024.
Quantum-Si (Nasdaq: QSI) has scheduled its third quarter 2024 financial results announcement for Tuesday, November 12, 2024. The company will host a conference call and webcast at 8:00 AM ET on the same day to discuss the results and provide a business update. Interested parties can access the webcast through the Investors section of Quantum-Si's website or register for a personalized dial-in number. A replay will be available after the event.
Quantum-Si Incorporated (Nasdaq: QSI), The Protein Sequencing Company™, has announced that its Compensation Committee has granted a total of 385,983 restricted stock units (RSUs) to five new employees under the company's 2023 Inducement Equity Incentive Plan. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as inducements for the new employees joining Quantum-Si.
The RSUs will vest according to the following schedule: 25% on December 20, 2025, with the remaining 75% vesting in 12 equal quarterly installments thereafter. Vesting is subject to the employees' continued employment with Quantum-Si. The RSUs are governed by the terms and conditions of the 2023 Inducement Plan and the respective RSU agreements.
Quantum-Si (Nasdaq: QSI) announced its participation at the Human Proteome Organization (HUPO) World Congress 2024 in Dresden, Germany. The company, known for Next-Generation Protein Sequencing™ (NGPS), will present data from its Platinum® instrument in two poster sessions:
1. Quantum-Si's Next-Generation Protein Sequencer™ for protein detection and peptide characterization from biological samples.
2. Integrated sequencing of single transcript and protein molecules to discern alternatively spliced tropomyosin proteoforms.
Additionally, Quantum-Si will host a breakfast talk on combining NGPS and top-down mass spectrometry for enhanced proteoform analysis. These presentations will showcase Platinum's capabilities in detecting protein variants, post-translational modifications, protein barcoding, and proteoform characterization.